Company profile: NeoPhore
1.1 - Company Overview
Company description
- Provider of novel small molecule cancer therapies that stimulate the immune system by targeting DNA mismatch repair to induce neoantigen expression and increase immunogenicity in solid tumors, including PMS2 and MLH1 modulators that convert immune-cold tumors to hot and enhance sensitivity to immune checkpoint inhibitors, plus continuous neoantigen creation and research and development on next-generation targets.
Products and services
- Continuous Neoantigen Creation: Mechanism-driven process generating new antigens from DNA mutations in tumor cells, enhancing the immune system's ability to recognize and attack cancer cells
- DNA Mismatch Repair Inhibitors: Pathway-specific small-molecule drugs that block DNA mismatch repair to induce neoantigen expression, increasing immunogenicity in solid tumors and exploiting weak spots in tumor cell defense mechanisms
- PMS2 Modulators: Protein-specific compounds that modulate PMS2 to convert immune 'cold' tumors to 'hot', increasing sensitivity to immune checkpoint inhibitors and enhancing antitumor immune recognition
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to NeoPhore
Raptor Pharma
HQ: United States
Website
- Description: Provider of biopharmaceutical therapeutics, engaging in discovery, research and preclinical development of drug candidates and drug-targeting platforms for brain and neurodegenerative diseases, genetic disorders and cancer, and commercializing TEPEZZA for Thyroid Eye Disease and UPLIZNA for neuromyelitis optica spectrum disorder in AQP4 antibody-positive adults.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Raptor Pharma company profile →
Bluebee
HQ: The Netherlands
Website
- Description: Provider of a secure global, cloud-based accelerated bio-informatics/genomics platform and high-performance genomics solutions to process, analyze, share and store large volumes of genomics data, enabling research and clinical labs to reduce cost and time-to-diagnose.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Bluebee company profile →
CTI BioPharma
HQ: United States
Website
- Description: Provider of biopharmaceutical oncology products for cancer treatment, focused on blood-related cancers. Develops, acquires, and commercializes therapies including Pixantrone (Phase III; non-Hodgkin's lymphoma), Brostallicin (first-line Phase II; sarcoma), and OPAXIO chemotherapeutic.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CTI BioPharma company profile →
Correlagen
HQ: United States
Website
- Description: Provider of genetic testing that helps physicians diagnose diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Correlagen company profile →
Purigen Biosystems
HQ: United States
Website
- Description: Provider of automated solutions for DNA and RNA purification using a proprietary approach with isotachophoresis to separate nucleic acids freely in solution without binding or stripping from a physical surface; technology is agnostic to nucleic acid size or sequence.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Purigen Biosystems company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for NeoPhore
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to NeoPhore
2.2 - Growth funds investing in similar companies to NeoPhore
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for NeoPhore
4.2 - Public trading comparable groups for NeoPhore
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →